Abeona Therapeutics Appoints Keith A. Goldan to Board of Directors and Audit Chair

Key Strategic Leadership Addition Aims to Drive Growth and Strengthen Financial Oversight

CLEVELAND, April 7, 2026 — Abeona Therapeutics Inc. (Nasdaq: ABEO) has announced the appointment of Keith A. Goldan as an independent member of its Board of Directors, effective April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona’s Audit Committee, a role that will be critical as the company advances its strategic and financial objectives as a commercial-stage biotechnology company.

Key Points from the Announcement

• Experienced Financial Leadership: Mr. Goldan brings over 20 years of financial leadership in publicly traded commercial-stage biotechnology and specialty pharmaceutical firms. His expertise includes capital markets, corporate development, and operational scaling.
• Current and Prior Roles:
  • Currently serves as Chief Financial Officer of Syndax Pharmaceuticals, where he guided the company through its first two product approvals and commercialization.
  • Previously served as CFO at Optinose, where he helped launch the company’s lead product in the U.S., and at Fibrocell, a cell and gene therapy company.
  • Held CFO and executive roles at NuPathe, PuriCore plc, Biosyn, as well as financial leadership positions at ViroPharma and KPMG.
• Broad Operational Experience: Led finance, accounting, IT, HR, and corporate development functions; raised capital via IPOs and other vehicles; executed multiple M&A transactions.
• Shareholder Relevance: Mr. Goldan’s appointment signals Abeona’s commitment to robust financial oversight and strategic growth, particularly as it navigates the commercial launch of its lead product, ZEVASKYN®.

Statements from Leadership

“On behalf of the Board, we are delighted to welcome Keith to Abeona,” said Michael Amoroso, Chairman of Abeona’s Board of Directors. “Keith’s deep experience in capital markets, corporate development, and operational scaling will be an invaluable voice as we continue to position Abeona for growth as a commercial-stage biotech company.”

“I am excited to join the Board of Directors at Abeona at this important time in the organization’s growth as commercial momentum continues to build for its first US launch,” said Mr. Goldan. “I look forward to partnering with the talented leadership team at Abeona to advance strategic priorities and drive value for patients and shareholders.”

About Abeona Therapeutics

Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases. Its lead product, ZEVASKYN® (prademagene zamikeracel), is the first and only autologous cell-based gene therapy approved for treating wounds in both adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company operates a cGMP manufacturing facility in Cleveland, Ohio, which supports the commercial production of ZEVASKYN.

Beyond ZEVASKYN, Abeona’s pipeline includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The company is also evaluating next-generation AAV capsids for a variety of devastating diseases.

Potential Price-Sensitive and Shareholder-Relevant Information

• Strengthened Financial Oversight: The appointment of Mr. Goldan, with his history of successfully raising capital and navigating commercialization milestones, could enhance investor confidence in Abeona’s financial strategy and execution.
• Commercial Momentum for ZEVASKYN: The company is building momentum for the U.S. launch of ZEVASKYN—a potentially transformative therapy for RDEB—which may represent a significant market opportunity and revenue inflection point.
• Ongoing Development Pipeline: Continued progress in the company’s rare disease portfolio and gene therapy pipeline, including ophthalmic and AAV programs, may offer additional upside for investors.
• Risks and Forward-Looking Statements: The company highlighted risks including commercialization execution, regulatory outcomes, ability to meet product demand, and external economic conditions. Shareholders should monitor developments related to ZEVASKYN’s commercial performance and pipeline progress.

Contact for Investors and Media

Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
[email protected]

Lee M. Stern
Meru Advisors
[email protected]

Disclaimer

This article contains forward-looking statements, including those regarding Abeona’s commercial prospects, regulatory outcomes, and pipeline development. Actual results could differ materially due to risks and uncertainties, including market conditions, regulatory reviews, and execution of strategic initiatives. This article is for informational purposes only and does not constitute investment advice. Investors should review Abeona’s filings with the SEC and consult financial advisors before making investment decisions.

View ABEONA THERAPEUTICS INC. Historical chart here